

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/731,899	12/08/2000	Benjamin Chain	20555/1203433-US1	1183	
7278 7:	590 10/05/2006	EXAMINER		INER	
DARBY & DARBY P.C.			SWARTZ, RODNEY P		
P. O. BOX 5257 NEW YORK, NY 10150-5257			ART UNIT	PAPER NUMBER	
,			1645	1645	
			DATE MAIL ED. 10/05/2004	,	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summany	09/731,899	CHAIN, BENJAMIN				
Office Action Summary	Examiner	Art Unit				
	Rodney P. Swartz, Ph.D.	1645				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be time Till apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. lely filed the mailing date of this communication. (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 27 Ju	ılv 2006.					
,	action is non-final.					
<i>,</i>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.						
4a) Of the above claim(s) 13-20 is/are withdraw	4a) Of the above claim(s) <u>13-20</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-12</u> is/are rejected.						
7) Claim(s) is/are objected to.	☐ Claim(s) is/are objected to.					
8) Claim(s) <u>1-20</u> are subject to restriction and/or e	election requirement.					
Application Papers						
9)⊠ The specification is objected to by the Examine	r.					
10)⊠ The drawing(s) filed on <u>08Dec2000</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).				
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau	ı (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date Notice of Informal Patent Application						
Paper No(s)/Mail Date <u>11/00,1/01,11/01</u> .	6) Other:	· ••				

Application/Control Number: 09/731,899

Art Unit: 1645

DETAILED ACTION

1. Applicant's Response to Restriction Requirement, received 17 July 2006, is acknowledged. Applicant elects, without traverse, Invention I, claims 1-12, drawn to peptides, classified in class 424, subclass 184.1.

Claims 1-20 are pending. Claims 13-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.

2. Claims 1-12 are under consideration.

Specification

3. The disclosure is objected to because of the following informalities:

Page 2, line 2, there is no listing of a reference "Dickson et al" only a "Dickerson et al".

Page 6, line 25, "rifampacin" should be "rifampicin".

Page 8, lines 20-24, there is no verb in the sentence.

Page 43, there is no volume number for the Sisodia et al., 1995 reference.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 1-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 09/731,899

Art Unit: 1645

Claims 1, 2, and 7 recite peptides or epitopes which are "derived" from a source. The metes and bounds of such a "derivation" is unclear because the specification does not define the term. Claims 3-6 and 8-12 depend from the claims, but do not clarify the indefiniteness.

6. Claim 3 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims is drawn to peptides having an amino acid sequence selected from the group consisting of SEQ ID Nos:2, 3, 4, 5, 6, 7, and "mixtures thereof". It is unclear what is meant by a "mixture" of SEQ ID Nos:2-7.

Conclusion

- 7. No claims are allowed.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's acting supervisor, Albert M. Navarro, can be reached on (571)272-0861.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Application/Control Number: 09/731,899

Art Unit: 1645

Page 4

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RODNEY P SWARTZ, PH.D PRIMARY EXAMINER Art Unit 1645

September 26, 2006